DexCom G6 for Type 2 Diabetes Mellitus

Phase-Based Progress Estimates
Type 2 Diabetes Mellitus+1 More
DexCom G6 - Device
All Sexes
What conditions do you have?

Study Summary

This trial will study how well a continuous glucose monitor works in people with type 2 diabetes who need insulin.

Eligible Conditions
  • Type 2 Diabetes Mellitus

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 12 weeks

12 weeks
Change in DTSQc scores
Percent change in TIR 70-180 mg/dl
The proportion of patients with % wear time >70% will be reported.

Trial Safety

Trial Design

1 Treatment Group

Dexcom CGM
1 of 1
Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: DexCom G6 · No Placebo Group · N/A

Dexcom CGM
Experimental Group · 1 Intervention: DexCom G6 · Intervention Types: Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 12 weeks

Who is running the clinical trial?

Kathleen DunganLead Sponsor
5 Previous Clinical Trials
325 Total Patients Enrolled
1 Trials studying Type 2 Diabetes Mellitus
42 Patients Enrolled for Type 2 Diabetes Mellitus
DexCom, Inc.Industry Sponsor
122 Previous Clinical Trials
13,024 Total Patients Enrolled
4 Trials studying Type 2 Diabetes Mellitus
197 Patients Enrolled for Type 2 Diabetes Mellitus
Kathleen Dungan, MDPrincipal InvestigatorOSU Medical Center

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have type 2 diabetes.\n
You have a hemoglobin A1c level of at least 8.0%.
You have a smartphone that is compatible with the Clarity App.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 29th, 2021

Last Reviewed: October 15th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.